THU0337 Evaluation of High-Throughput Platforms for Digital Antinuclear Antibody (ANA) Indirect Immunofluorescence (IFA) Screening
Background ANA screening is a gateway test in the laboratory evaluation of autoimmunity. High-throughput enzyme immunoassays (EIAs) have largely replaced traditional IFA methods but have raised concerns about the limited number of antigen specificities included on immunobeads and about batch variati...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A279 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | Suppl 3 |
container_start_page | A279 |
container_title | Annals of the rheumatic diseases |
container_volume | 72 |
creator | Zarabpouri, F. Zambales, M.-L. V. Miralles, V. O. Pizarro, T. T. Popov, J. M. Naides, S. J. |
description | Background ANA screening is a gateway test in the laboratory evaluation of autoimmunity. High-throughput enzyme immunoassays (EIAs) have largely replaced traditional IFA methods but have raised concerns about the limited number of antigen specificities included on immunobeads and about batch variation of antigen content in cell lysate based EIAs. A return to traditional, manual ANA IFA is impeded by labor intensity, lack of standardization, interobserver variation, and the need for highly-trained technical staff. Objectives A high-throughput IFA method with observer consistency and ease of quality control and monitoring is desirable. To find such a method, we evaluated the performance of 3 commercial platforms for digital ANA IFA image acquisition and analysis. Methods The 3 digital ANA IFA platforms each employed proprietary HEp-2 slides and antihuman IgG fluorescein conjugates. Results were compared with those obtained using manual IFA on a proprietary HEp-2 cell substrate that used an antihuman polyvalent immunoglobulin conjugate. Results were interpreted by a single senior laboratory scientist. Results Normal donor (n=120) and ≥153 patient samples submitted for testing were evaluated by manual ANA IFA and on each digital platform. Initial platform screening using the original factory settings indicated the need to adjust the instrument threshold of positivity to approximate the performance of the manual method, which we used as the gold standard. For platform 1, fluorescence intensity positive threshold values of 66, 147, 180, 219, and 280 Units yielded sensitivities of 98%, 90%, 90%, 86%, and 83%, and specificities of 33%, 71%, 78%, 86%, and 92%, respectively. Digital platform specificity was low before we adjusted the threshold for positivity. After detection thresholds were optimized, all 3 platforms were evaluated against the manual IFA (Table). Aligning the platform threshold for positivity with that of the manual method improved specificity without significantly altering sensitivity. Discordant samples tended to have low titer by digital or manual methods. Samples negative by the digital methods but positive by the manual method tended to have nucleolar ANA patterns, several with moderate titers. Conclusions Thresholds based on total field intensity units may fail to recognize more discrete patterns such as nucleolar or nuclear dots. Technologists should review all images generated on digital platforms to confirm positivity versus negativity and |
doi_str_mv | 10.1136/annrheumdis-2013-eular.865 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777914474</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008732551</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1634-e9a3da2884f3f1cf56b87adb34c54af25bd699bb1cda8aa832b9361c4ef9142f3</originalsourceid><addsrcrecordid>eNqVkEFvFCEYhidGE9fW_0D0Ug_TwsAA421dW3eTyWriVhMvhGFgl3UGVhiMvXmof9RfUto1xqsX4CPP-73JUxQvEDxHCNML6VzY6TT2NpYVRLjUaZDhnNP6UTFDhPL8S-HjYgYhxCVpKHtaPItxn0fIEZ8Vt5vlNcSY_f756_K7HJKcrHfAG7C021252QWftrtDmsCHQU7GhzGCfIK3dmsnOYC5m6xLatAyPLw739-As_l6_gqsXG-DVhNYjWNy3gzJBx2VdkqDs9VVJj6qoLWzbntaPDFyiPr5n_ukuL663CyWZfv-3Woxb8sOUUxK3Ujcy4pzYrBBytS040z2HSaqJtJUddfTpuk6pHrJpeS46hpMkSLaNIhUBp8UL497D8F_SzpOYu9TcLlSIMZYhggjmXp9pFTwMQZtxCHYUYYbgaC4ty7-sS7urYsH6yJbz-HyGLZx0j_-JmX4KijDrBbrTwvxpv7Sfm7XXLSZr498N-7_p-cOo02fDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777914474</pqid></control><display><type>article</type><title>THU0337 Evaluation of High-Throughput Platforms for Digital Antinuclear Antibody (ANA) Indirect Immunofluorescence (IFA) Screening</title><source>BMJ Journals - NESLi2</source><creator>Zarabpouri, F. ; Zambales, M.-L. V. ; Miralles, V. O. ; Pizarro, T. T. ; Popov, J. M. ; Naides, S. J.</creator><creatorcontrib>Zarabpouri, F. ; Zambales, M.-L. V. ; Miralles, V. O. ; Pizarro, T. T. ; Popov, J. M. ; Naides, S. J.</creatorcontrib><description>Background ANA screening is a gateway test in the laboratory evaluation of autoimmunity. High-throughput enzyme immunoassays (EIAs) have largely replaced traditional IFA methods but have raised concerns about the limited number of antigen specificities included on immunobeads and about batch variation of antigen content in cell lysate based EIAs. A return to traditional, manual ANA IFA is impeded by labor intensity, lack of standardization, interobserver variation, and the need for highly-trained technical staff. Objectives A high-throughput IFA method with observer consistency and ease of quality control and monitoring is desirable. To find such a method, we evaluated the performance of 3 commercial platforms for digital ANA IFA image acquisition and analysis. Methods The 3 digital ANA IFA platforms each employed proprietary HEp-2 slides and antihuman IgG fluorescein conjugates. Results were compared with those obtained using manual IFA on a proprietary HEp-2 cell substrate that used an antihuman polyvalent immunoglobulin conjugate. Results were interpreted by a single senior laboratory scientist. Results Normal donor (n=120) and ≥153 patient samples submitted for testing were evaluated by manual ANA IFA and on each digital platform. Initial platform screening using the original factory settings indicated the need to adjust the instrument threshold of positivity to approximate the performance of the manual method, which we used as the gold standard. For platform 1, fluorescence intensity positive threshold values of 66, 147, 180, 219, and 280 Units yielded sensitivities of 98%, 90%, 90%, 86%, and 83%, and specificities of 33%, 71%, 78%, 86%, and 92%, respectively. Digital platform specificity was low before we adjusted the threshold for positivity. After detection thresholds were optimized, all 3 platforms were evaluated against the manual IFA (Table). Aligning the platform threshold for positivity with that of the manual method improved specificity without significantly altering sensitivity. Discordant samples tended to have low titer by digital or manual methods. Samples negative by the digital methods but positive by the manual method tended to have nucleolar ANA patterns, several with moderate titers. Conclusions Thresholds based on total field intensity units may fail to recognize more discrete patterns such as nucleolar or nuclear dots. Technologists should review all images generated on digital platforms to confirm positivity versus negativity and identify patterns that may be overlooked by digital analysis algorithms. Disclosure of Interest F. Zarabpouri Employee of: Quest Diagnostics Nichols Institute, M.-L. Zambales Employee of: Quest Diagnostics Nichols Institute, V. Miralles Employee of: Quest Diagnostics Nichols Institute, T. Pizarro Employee of: Quest Diagnostics Nichols Institute, J. Popov Employee of: Quest Diagnostics Nichols Institute, S. Naides Employee of: Quest Diagnostics Nichols Institute</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2013-eular.865</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A279</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A279.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A279.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77342,77373</link.rule.ids></links><search><creatorcontrib>Zarabpouri, F.</creatorcontrib><creatorcontrib>Zambales, M.-L. V.</creatorcontrib><creatorcontrib>Miralles, V. O.</creatorcontrib><creatorcontrib>Pizarro, T. T.</creatorcontrib><creatorcontrib>Popov, J. M.</creatorcontrib><creatorcontrib>Naides, S. J.</creatorcontrib><title>THU0337 Evaluation of High-Throughput Platforms for Digital Antinuclear Antibody (ANA) Indirect Immunofluorescence (IFA) Screening</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background ANA screening is a gateway test in the laboratory evaluation of autoimmunity. High-throughput enzyme immunoassays (EIAs) have largely replaced traditional IFA methods but have raised concerns about the limited number of antigen specificities included on immunobeads and about batch variation of antigen content in cell lysate based EIAs. A return to traditional, manual ANA IFA is impeded by labor intensity, lack of standardization, interobserver variation, and the need for highly-trained technical staff. Objectives A high-throughput IFA method with observer consistency and ease of quality control and monitoring is desirable. To find such a method, we evaluated the performance of 3 commercial platforms for digital ANA IFA image acquisition and analysis. Methods The 3 digital ANA IFA platforms each employed proprietary HEp-2 slides and antihuman IgG fluorescein conjugates. Results were compared with those obtained using manual IFA on a proprietary HEp-2 cell substrate that used an antihuman polyvalent immunoglobulin conjugate. Results were interpreted by a single senior laboratory scientist. Results Normal donor (n=120) and ≥153 patient samples submitted for testing were evaluated by manual ANA IFA and on each digital platform. Initial platform screening using the original factory settings indicated the need to adjust the instrument threshold of positivity to approximate the performance of the manual method, which we used as the gold standard. For platform 1, fluorescence intensity positive threshold values of 66, 147, 180, 219, and 280 Units yielded sensitivities of 98%, 90%, 90%, 86%, and 83%, and specificities of 33%, 71%, 78%, 86%, and 92%, respectively. Digital platform specificity was low before we adjusted the threshold for positivity. After detection thresholds were optimized, all 3 platforms were evaluated against the manual IFA (Table). Aligning the platform threshold for positivity with that of the manual method improved specificity without significantly altering sensitivity. Discordant samples tended to have low titer by digital or manual methods. Samples negative by the digital methods but positive by the manual method tended to have nucleolar ANA patterns, several with moderate titers. Conclusions Thresholds based on total field intensity units may fail to recognize more discrete patterns such as nucleolar or nuclear dots. Technologists should review all images generated on digital platforms to confirm positivity versus negativity and identify patterns that may be overlooked by digital analysis algorithms. Disclosure of Interest F. Zarabpouri Employee of: Quest Diagnostics Nichols Institute, M.-L. Zambales Employee of: Quest Diagnostics Nichols Institute, V. Miralles Employee of: Quest Diagnostics Nichols Institute, T. Pizarro Employee of: Quest Diagnostics Nichols Institute, J. Popov Employee of: Quest Diagnostics Nichols Institute, S. Naides Employee of: Quest Diagnostics Nichols Institute</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkEFvFCEYhidGE9fW_0D0Ug_TwsAA421dW3eTyWriVhMvhGFgl3UGVhiMvXmof9RfUto1xqsX4CPP-73JUxQvEDxHCNML6VzY6TT2NpYVRLjUaZDhnNP6UTFDhPL8S-HjYgYhxCVpKHtaPItxn0fIEZ8Vt5vlNcSY_f756_K7HJKcrHfAG7C021252QWftrtDmsCHQU7GhzGCfIK3dmsnOYC5m6xLatAyPLw739-As_l6_gqsXG-DVhNYjWNy3gzJBx2VdkqDs9VVJj6qoLWzbntaPDFyiPr5n_ukuL663CyWZfv-3Woxb8sOUUxK3Ujcy4pzYrBBytS040z2HSaqJtJUddfTpuk6pHrJpeS46hpMkSLaNIhUBp8UL497D8F_SzpOYu9TcLlSIMZYhggjmXp9pFTwMQZtxCHYUYYbgaC4ty7-sS7urYsH6yJbz-HyGLZx0j_-JmX4KijDrBbrTwvxpv7Sfm7XXLSZr498N-7_p-cOo02fDw</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Zarabpouri, F.</creator><creator>Zambales, M.-L. V.</creator><creator>Miralles, V. O.</creator><creator>Pizarro, T. T.</creator><creator>Popov, J. M.</creator><creator>Naides, S. J.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>THU0337 Evaluation of High-Throughput Platforms for Digital Antinuclear Antibody (ANA) Indirect Immunofluorescence (IFA) Screening</title><author>Zarabpouri, F. ; Zambales, M.-L. V. ; Miralles, V. O. ; Pizarro, T. T. ; Popov, J. M. ; Naides, S. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1634-e9a3da2884f3f1cf56b87adb34c54af25bd699bb1cda8aa832b9361c4ef9142f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zarabpouri, F.</creatorcontrib><creatorcontrib>Zambales, M.-L. V.</creatorcontrib><creatorcontrib>Miralles, V. O.</creatorcontrib><creatorcontrib>Pizarro, T. T.</creatorcontrib><creatorcontrib>Popov, J. M.</creatorcontrib><creatorcontrib>Naides, S. J.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zarabpouri, F.</au><au>Zambales, M.-L. V.</au><au>Miralles, V. O.</au><au>Pizarro, T. T.</au><au>Popov, J. M.</au><au>Naides, S. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THU0337 Evaluation of High-Throughput Platforms for Digital Antinuclear Antibody (ANA) Indirect Immunofluorescence (IFA) Screening</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>72</volume><issue>Suppl 3</issue><spage>A279</spage><pages>A279-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background ANA screening is a gateway test in the laboratory evaluation of autoimmunity. High-throughput enzyme immunoassays (EIAs) have largely replaced traditional IFA methods but have raised concerns about the limited number of antigen specificities included on immunobeads and about batch variation of antigen content in cell lysate based EIAs. A return to traditional, manual ANA IFA is impeded by labor intensity, lack of standardization, interobserver variation, and the need for highly-trained technical staff. Objectives A high-throughput IFA method with observer consistency and ease of quality control and monitoring is desirable. To find such a method, we evaluated the performance of 3 commercial platforms for digital ANA IFA image acquisition and analysis. Methods The 3 digital ANA IFA platforms each employed proprietary HEp-2 slides and antihuman IgG fluorescein conjugates. Results were compared with those obtained using manual IFA on a proprietary HEp-2 cell substrate that used an antihuman polyvalent immunoglobulin conjugate. Results were interpreted by a single senior laboratory scientist. Results Normal donor (n=120) and ≥153 patient samples submitted for testing were evaluated by manual ANA IFA and on each digital platform. Initial platform screening using the original factory settings indicated the need to adjust the instrument threshold of positivity to approximate the performance of the manual method, which we used as the gold standard. For platform 1, fluorescence intensity positive threshold values of 66, 147, 180, 219, and 280 Units yielded sensitivities of 98%, 90%, 90%, 86%, and 83%, and specificities of 33%, 71%, 78%, 86%, and 92%, respectively. Digital platform specificity was low before we adjusted the threshold for positivity. After detection thresholds were optimized, all 3 platforms were evaluated against the manual IFA (Table). Aligning the platform threshold for positivity with that of the manual method improved specificity without significantly altering sensitivity. Discordant samples tended to have low titer by digital or manual methods. Samples negative by the digital methods but positive by the manual method tended to have nucleolar ANA patterns, several with moderate titers. Conclusions Thresholds based on total field intensity units may fail to recognize more discrete patterns such as nucleolar or nuclear dots. Technologists should review all images generated on digital platforms to confirm positivity versus negativity and identify patterns that may be overlooked by digital analysis algorithms. Disclosure of Interest F. Zarabpouri Employee of: Quest Diagnostics Nichols Institute, M.-L. Zambales Employee of: Quest Diagnostics Nichols Institute, V. Miralles Employee of: Quest Diagnostics Nichols Institute, T. Pizarro Employee of: Quest Diagnostics Nichols Institute, J. Popov Employee of: Quest Diagnostics Nichols Institute, S. Naides Employee of: Quest Diagnostics Nichols Institute</abstract><cop>Kidlington</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2013-eular.865</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A279 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_journals_1777914474 |
source | BMJ Journals - NESLi2 |
title | THU0337 Evaluation of High-Throughput Platforms for Digital Antinuclear Antibody (ANA) Indirect Immunofluorescence (IFA) Screening |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T10%3A17%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THU0337%E2%80%85Evaluation%20of%20High-Throughput%20Platforms%20for%20Digital%20Antinuclear%20Antibody%20(ANA)%20Indirect%20Immunofluorescence%20(IFA)%20Screening&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Zarabpouri,%20F.&rft.date=2013-06&rft.volume=72&rft.issue=Suppl%203&rft.spage=A279&rft.pages=A279-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2013-eular.865&rft_dat=%3Cproquest_cross%3E4008732551%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777914474&rft_id=info:pmid/&rfr_iscdi=true |